Core Viewpoint - The company, Morning Light Bio, is experiencing a decline in stock price and is undergoing a significant ownership change in one of its subsidiaries, which may impact its financial reporting and operations [1] Company Overview - Morning Light Bio focuses on the research, production, and sales of plant extracts, with applications in food, health products, and cosmetics [1] - Key products include capsanthin, lutein, and steviol glycosides, which are natural plant extracts [1] Recent Developments - On August 20, the company announced that its wholly-owned subsidiary, Hebei Morning Light Pharmaceutical, plans to transfer 97.5% of its stake in Hebei Morning Light Tianrun Pharmaceutical to Sichuan Tongsheng Biopharmaceutical [1] - Following the transfer, Morning Light Tianrun Pharmaceutical will no longer be included in the company's consolidated financial statements [1] - As of July 31, 2025, the company has a loan balance of 70.7824 million yuan to Morning Light Tianrun Pharmaceutical [1] Market Activity - On August 21, the stock price was reported at 13.67 yuan, reflecting a decrease of 1.87% from the previous trading day [1] - The trading volume for that day was 97,213 hands, with a transaction amount of 134 million yuan [1] - On the same day, the net inflow of main funds was 1.9326 million yuan, accounting for 0.04% of the circulating market value [1] - Over the past five days, the cumulative net outflow of main funds reached 20.7632 million yuan, representing 0.38% of the circulating market value [1]